Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | ATP4A | P20648 | 16/20 | 0.39 |
| ▸ | ATP4B | P51164 | 16/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL534215 | 0.88 | ALOX5 (0.39) | MAPTRAB9AMEN1KMT2AATP4A | |
| SCHEMBL533701 | 0.79 | MAPT (0.45) | MAPTRAB9AMEN1KMT2AATP4A | |
| SCHEMBL533598 | 0.75 | RAB9A (0.35) | MAPTRAB9AMEN1KMT2AMAPK1 | |
| SCHEMBL532989 | 0.75 | RAB9A (0.35) | MAPTRAB9AMEN1KMT2AMAPK1 | |
| SCHEMBL533154 | 0.73 | LOXL2 (0.49) | MAPTRAB9AMEN1KMT2AMAPK1 | |
| SCHEMBL534343 | 0.73 | RAB9A (0.46) | MAPTRAB9AMEN1KMT2AMAPK1 | |
| SCHEMBL533358 | 0.72 | LOXL2 (0.44) | MAPTRAB9AMEN1KMT2AMAPK1 | |
| SCHEMBL533347 | 0.72 | ALDH1A1 (0.34) | MAPTRAB9AMEN1KMT2ANPC1 | |
| SCHEMBL533569 | 0.72 | ALDH1A1 (0.34) | MAPTRAB9AMEN1KMT2ANPC1 | |
| SCHEMBL533127 | 0.72 | ALOX5 (0.39) | MAPTRAB9AMEN1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2415763-B1 | PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING GLAUCOMA | UBE INDUSTRIES (JP) | 2016-01-27 | — | — | EP | disclosed |
| CN-102448940-B | For the medical composition of glaucomatous treatment or prevention | UBE INDUSTRIES, LTD. (JP) | 2015-10-21 | — | — | CN | disclosed |
| US-20140113907-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | UBE INDUSTRIES, LTD. (JP) | 2014-04-24 | — | — | US | disclosed |
| US-8648097-B2 | Pyridylaminoacetic acid compound | UBE INDUSTRIES, LTD. (JP) | 2014-02-11 | — | — | US | disclosed |
| US-20120190852-A1 | MEDICAL COMPOSITION FOR TREATMENT OR PROPHYLAXIS OF GLAUCOMA | UBE INDUSTRIES, LTD. (JP) | 2012-07-26 | — | — | US | disclosed |
| CN-102448940-A | Pharmaceutical composition for treating or preventing glaucoma | UBE INDUSTRIES | 2012-05-09 | — | — | CN | disclosed |
| EP-2415763-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING GLAUCOMA | Ube Industries, Ltd. (JP) | 2012-02-08 | — | — | EP | disclosed |
| US-20110054172-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | UBE CORPORATION (JP) | 2011-03-03 | — | — | US | disclosed |
| EP-2264009-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | Ube Industries, Ltd. (JP) | 2010-12-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140113907-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | PTGER2, PTGER1, PTGDR2 | MAPT 4180/4885RAB9A 2549/4885MEN1 4120/4885 |
| US-20110054172-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | PTGER2, PTGER1, PTGDR2 | MAPT 4449/4885RAB9A 2112/4885MEN1 4385/4885 |
| US-20120190852-A1 | MEDICAL COMPOSITION FOR TREATMENT OR PROPHYLAXIS OF GLAUCOMA | F12, C1S, AKR1C3 | MAPT 3554/4885RAB9A 1700/4885MEN1 1413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.